BioSeek named Michael Gallatin and Roy Whitfield to its board of directors, the company said this week.
Gallatin was most recently vice president and scientific director at ICOS. Prior to that, Gallatin was a faculty member at Fred Hutchinson Cancer Research Center. He has also joined BioSeek's advisory board, BioSeek said.
Whitfield most recently served as CEO and chairman of Incyte, which he co-founded in 1991. He will serve as business advisor to BioSeek.
Kenneth Coleman has been elected chairman of Accelrys, the company said this week.
Coleman has served as a director at Accelrys since May 2003, and has been the company's independent lead director since May 2004, Accelrys said.
NovaScreen Bioscience, a Caliper Life Sciences company, this week announced the release of General Side Effect II (GEN SEP II) panel, a specialized side-effect screening service.
The new panel evolved from NovaScreen's original general side effect profile panel, and incorporates a broader range of receptor subtype assays, NovaScreen said. GEN SEP II addresses side effects across a broad range of therapeutic areas including immunology, cancer, inflammation, pain, gastrointestinal, metabolic, neurological, and cardiovascular, NovaScreen said.
Geron this week commercially launched a T HESC cells, a new immortalized human cell line, available through American Type Culture Collection.
T HESC is a human endometrium fibroblast-like cell line immortalized with human telomerase reverse transcriptase. The endometrial cells used to produce the cell line were obtained from an endometrial hybridoma, Geron said. This is the fourth telomerase-immortalized cell line offered by ATCC as part of its Cell Immortalization Program. These cells provide a stable, uniform cell population for functional cell-based assays and long-term gene expression studies, Geron said.